The estimated Net Worth of Peter D Meldrum is at least $7.61 Milion dollars as of 5 November 2014. Peter Meldrum owns over 4,329 units of Myriad Genetics stock worth over $285,637 and over the last 22 years Peter sold MYGN stock worth over $7,323,189.
Peter has made over 52 trades of the Myriad Genetics stock since 2004, according to the Form 4 filled with the SEC. Most recently Peter exercised 4,329 units of MYGN stock worth $100,043 on 5 November 2014.
The largest trade Peter's ever made was exercising 123,940 units of Myriad Genetics stock on 5 February 2014 worth over $992,759. On average, Peter trades about 16,498 units every 50 days since 2003. As of 5 November 2014 Peter still owns at least 10,869 units of Myriad Genetics stock.
You can see the complete history of Peter Meldrum stock trades at the bottom of the page.
Peter's mailing address filed with the SEC is , , , , .
Over the last 22 years, insiders at Myriad Genetics have traded over $51,783,466 worth of Myriad Genetics stock and bought 61,160 units worth $1,252,955 . The most active insiders traders include Jerry S Lanchbury, Peter D Meldrum oraz Arthur H Jr Hayes. On average, Myriad Genetics executives and independent directors trade stock every 18 days with the average trade being worth of $563,312. The most recent stock trade was executed by Heinrich Dreismann on 9 September 2024, trading 10,000 units of MYGN stock currently worth $270,500.
myriad genetics inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. myriad is focused on three strategic imperatives: maintaining leadership in an expanding hereditary cancer market, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. for more information on how myriad is making a difference, please visit the company's website: www.myriad.com.
Myriad Genetics executives and other stock owners filed with the SEC include: